Sunshine Biopharma (Sunshine Biopharma) 6-1 Month Momentum % : -96.97% (As of May. 31, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-31), Sunshine Biopharma's 6-1 Month Momentum % is -96.97%.

The industry rank for Sunshine Biopharma's 6-1 Month Momentum % or its related term are showing as below:

SBFM's 6-1 Month Momentum % is ranked worse than
100% of 1117 companies
in the Drug Manufacturers industry
Industry Median: -3.13 vs SBFM: -96.97

Competitive Comparison of Sunshine Biopharma's 6-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Biopharma's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's 6-1 Month Momentum % falls into.

Sunshine Biopharma (NAS:SBFM) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma (NAS:SBFM) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Sunshine Biopharma 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Executives

Camille Sebaaly	director, officer: CFO and Secretary	14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun	10 percent owner	1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller	director	10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey	director	6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish	director	6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah	director	924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp	10 percent owner	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty	director, 10 percent owner, officer: CEO and President	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki	director, officer: Chief Operating Officer	731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di	director, officer: Chief Operating Officer	3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3